New drug cocktail aims to wipe out hidden myeloma cells after transplant

NCT ID NCT04876248

Ongoing Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether combining belantamab mafodotin (a targeted antibody-drug conjugate) with lenalidomide can eliminate minimal residual disease in multiple myeloma patients who still have detectable cancer after a stem cell transplant. The study enrolls 4 adults who are not yet cancer-free after transplant. The goal is to see if this approach can achieve undetectable cancer levels and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin and lenalidomide
What this could lead to: If successful, this could help more multiple myeloma patients achieve undetectable cancer levels after transplant, potentially improving long-term outcomes.
What could go wrong: This is a very small early-phase trial with only 4 participants, so results may not apply broadly. The drug combination also carries risks like eye problems and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA

Contacts and locations

Locations

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.